To the full analysis
BioNTech stock: growth
BNTXBioNTech reported $3.05B in revenue for fiscal 2025, up 0.2% on the prior year, up 41.7% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
60.8%
per year from 2017 to 2025, per share 59.6%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2017 | |
|---|---|---|
| Revenue | 41.7% | 60.8% |
| Revenue per share | 41.0% | 59.6% |
| Earnings | no data | no data |
| Earnings per share | no data | no data |
| Free cash flow | no data | no data |
| Free cash flow per share | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2017 | $68.26M | −$94.91M | −$122.23M |
| 2018 | $141.37M | −$53.21M | −$139.66M |
| 2019 | $120.34M | −$198.46M | −$298.74M |
| 2020 | $534.44M | $16.84M | −$109.59M |
| 2021 | $21.03B | $11.41B | $815.23M |
| 2022 | $19.18B | $10.45B | $14.64B |
| 2023 | $4.23B | $1.03B | $5.17B |
| 2024 | $3.05B | −$737.22M | −$271.04M |
| 2025 | $3.05B | −$1.21B | $298.98M |
Revenue by region
Where BioNTech SE generates its revenue.
- United States$2.0B65%
- Germany$841.2M28%
- Ireland$337.7M11%
The company split earlier years differently. A history would not be comparable, so only 2025 is shown.
Figures as a table
| 2025 | Share 2025 | |
|---|---|---|
| United States | $1.99B | 65.1% |
| Germany | $841.16M | 27.5% |
| Ireland | $337.75M | 11.1% |
| Total revenue | $3.05B | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 12 Sep 2025)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.